<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00229502</url>
  </required_header>
  <id_info>
    <org_study_id>10066</org_study_id>
    <nct_id>NCT00229502</nct_id>
  </id_info>
  <brief_title>Cognitive Effects of Immunomodulatory Drugs in MS</brief_title>
  <official_title>Comparison of the Cognitive Effects of Three Immunomodulatory Drugs in Relapsing-Remitting Multiple Sclerosis: A Longitudinal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sharon Lynch, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine and compare changes in the specific thinking skills
      of patients with RRMS who are receiving treatment with one of three immunomodulatory
      medications (Avonex, Copaxone, or Rebif).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition this study will compare the patients' personal view of how they are doing, any
      changes in physical disability, and the frequency and severity of relapses over the three
      year period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">96</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Subjects receiving Avonex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Subjects receiving Rebif</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Subjects receiving Copaxone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>Healthy controls</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Multiple sclerosis clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RRMS for at least one year,

          -  Currently on one of three immunomodulatory drugs (Avonex, Copaxone, or Rebif),

          -  Visual Acuity is 20/50 or better,

          -  patient has four color vision,

          -  Must have at least a high school education

        Exclusion Criteria:

          -  History of head injury, drug/alcohol abuse, and/or psychiatric problems, -current
             diagnosis of a severe or lifethreatening disease other than MS,

          -  currently taking immunosuppressant medication,

          -  resides greater than 200 miles from the study site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon G Lynch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas R Denney, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2005</study_first_submitted>
  <study_first_submitted_qc>September 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2005</study_first_posted>
  <last_update_submitted>March 21, 2012</last_update_submitted>
  <last_update_submitted_qc>March 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Sharon Lynch, MD</investigator_full_name>
    <investigator_title>Professor and Director of MS Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

